In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterized by the inability to relax muscles following voluntary contraction
The agreement is for the development and commercialisation of JHU’s novel target and technology that will help patients with colorectal cancer
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Biocon has reported consolidated financial results for the period ended December 31, 2021
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Subscribe To Our Newsletter & Stay Updated
